Healthy high growth potential

Results

1541

Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.

1541 companies

CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv YieldIndustry
TMGH
ج.م97.88-1.1%75.3%ج.م201.7bج.م141.9013.135.9%0.3%Real Estate Management and Development
ADMR
Rp1,680.003.7%66.3%Rp68.7tRp2,344.8613.126.8%2.8%Materials
A458870
₩23,950.004.1%112.6%₩911.5b₩62,666.6730.040.0%n/aHealthcare
FWRY
ج.م19.31-0.4%45.3%ج.م65.8bج.م22.4524.727.3%n/aDiversified Financials
CDR
zł263.102.3%3.2%zł26.3bzł234.5150.939.0%0.4%Media
AGP
€7.262.4%-11.5%€132.4m€8.5726.639.1%n/aCapital Goods
WAYS
SEK 39.401.3%0%SEK 345.5mSEK 58.00209.778.5%0%Tech
RHM
€1,202.005.2%-27.1%€56.1b€1,679.3846.430.5%1.0%Capital Goods
AAZ
UK£4.08-1.2%150.8%UK£465.9mUK£5.6835.725.9%0.7%Materials
MDGL
US$507.56-1.5%29.7%US$11.7bUS$678.069.163.7%n/aPharmaceuticals & Biotech
LPK
€15.05-3.5%87.4%€368.0m€22.753.7116.6%0%Tech
4417
JP¥4,520.00-2.4%38.9%JP¥71.4bJP¥5,800.0042.226.4%1.1%Software
9218
JP¥761.001.1%-10.0%JP¥7.9bn/a33.628.9%1.3%Healthcare
TGTX
US$48.74-0.9%75.8%US$6.9bUS$69.7115.721.3%n/aPharmaceuticals & Biotech
456A
JP¥1,402.00-2.6%n/aJP¥131.0bn/a39.723.4%n/aRetail
NVDA
US$225.163.5%23.7%US$5.5tUS$302.8334.222.9%0.4%Semiconductors
AXSM
US$213.67-3.3%92.3%US$11.2bUS$285.4214.461.1%n/aPharmaceuticals & Biotech
688300
CN¥166.4712.3%184.0%CN¥39.8bCN¥151.00132.740.3%0.3%Materials
688700
CN¥61.203.6%26.0%CN¥17.2bCN¥61.67102.861.7%0.6%Capital Goods
301345
CN¥270.994.0%57.6%CN¥27.8bCN¥320.3532.631.5%1.1%Automobiles
3881
HK$19.95-6.5%n/aHK$8.7bn/a5.9119.5%n/aCapital Goods
688192
CN¥61.339.8%-27.0%CN¥28.3bCN¥83.0031.9104.5%n/aPharmaceuticals & Biotech
MONOLITH
₹1,007.5513.0%155.7%₹20.7b₹1,060.0076.435.6%n/aMaterials
3277
HK$77.358.5%n/aHK$32.6bHK$115.35100.634.2%0.4%Tech
Page 1 of 43
Healthy high growth potential - Investing Ideas - Simply Wall St